Mingliang Wang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Anti Inflammatory

Radiation Induced

Dna Damage Response

Top Venues

Journal of medicinal chemistry

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

This page only lists publications with an associated author ORCID identifier.

Publications

Zhi Liu, Kailong Jiang, Yan Liu, Junfei Li, Siqi Huang, Ping Li, Lei Xu, Xiaomin Xu, Xiaobei Hu, Xia Zeng, Zehui Huang, Yubo Zhou, Jia Li, Kai Long, Mingliang Wang
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. Journal of medicinal chemistry 67 (15) (2024)
Zhi Liu, Kailong Jiang, Yan Liu, Junfei Li, Siqi Huang, Ping Li, Lei Xu, Xiaomin Xu, Xiaobei Hu, Xia Zeng, Zehui Huang, Yubo Zhou, Jia Li, Kai Long, Mingliang Wang
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. Journal of medicinal chemistry (2024)
Lijun Wang, Huiliang Yang, Changwei Wang, Mingliang Wang, Jiahui Huang, Thedoe Nyunt, Camilo Osorio, Shi-Yong Sun, Maurizio Pacifici, Veronique Lefebvre, Douglas C Moore, Shaomeng Wang, Wentian Yang
SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 (17) (2024)
Zhi Liu, Kailong Jiang, Yan Liu, Junfei Li, Siqi Huang, Ping Li, Lei Xu, Xiaomin Xu, Xiaobei Hu, Xia Zeng, Zehui Huang, Yubo Zhou, Jia Li, Kai Long, Mingliang Wang
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. Journal of medicinal chemistry 67 (15) (2024)
Zhi Liu, Kailong Jiang, Yan Liu, Junfei Li, Siqi Huang, Ping Li, Lei Xu, Xiaomin Xu, Xiaobei Hu, Xia Zeng, Zehui Huang, Yubo Zhou, Jia Li, Kai Long, Mingliang Wang
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. Journal of medicinal chemistry (2024)